David Dearnaley, MA, MD, FRCP, FRCR, The Institute of Cancer Reseach and The Royal Marsden NHS Foundation Trust, London, UK, gives us his highlights from ESTRO 2022 and discusses recent advances and future directions for radiotherapy in both metastatic and localised prostate cancer. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
